Hematopoietic stem cell transplant patient

Mullen CA, Nair J, Sandesh S, Chan KW. Fever and neutropenia in pediatric hematopoietic stem cell transplant patients. Bone Marrow Transplant 2000 25(l) 59-65. 

Bacigalupo A, Boyd A, Slipper J, Curtis J, Clissold S. Foscamet in the management of cytomegalovirus infections in hematopoietic stem cell transplant patients. Expert Rev Anti Infect Ther 2012 10(ll) 1249-64. 

Following hematopoietic stem cell transplantation the patient will need virtually all routine vaccines to be administered again however, the patient will not be able to mount an adequate response for 6 to 12 months post-transplant. Diphtheria, tetanus, acellular pertussis, Haemophilus influenzae type b, hepatitis B, pneumococcal, and inactivated poliovirus should be given at 12,14, and 24 months post-hematopoietic stem cell transplantation. Inactivated influenza vaccine should be given yearly, starting 6 months after transplant. Measles, mumps and rubella can be given 2 years after transplant and varicella vaccine is contraindicated.16... 

Allogeneic hematopoietic stem cell transplantation (HSCT) has been used in the treatment of pediatric AML in first complete remission. In most clinical trials, the availability of HLA-matched sibling donors determined whether patients underwent HSCT as postremission treatment. To facilitate this process, it is important to obtain HLA typing on all younger patients with AML and siblings shortly after diagnosis. Patients who do not have an HLA-matched sibling will proceed to postremission therapy. 

Patients who relapse after an initial complete response can be treated with the same regimen, a non-cross-resistant regimen, radiation therapy, or high-dose chemotherapy and autologous hematopoietic stem cell transplantation (HSCT). 

Autologous non-myeloablative hematopoietic stem cell transplantation in patients with systemic sclerosis. Bone Marrow Transplant 2007 40 549-555. 

Up until the 1970s, CML was incurable. The development of allogeneic hematopoietic stem cell transplantation (HSCT) was subsequently shown to provide long-term disease eradication with prolonged disease-free survival (14). However, allogeneic HSCT is available to only a minority of patients because of the necessity of finding a suitable donor for transplantation and the toxicity of the procedure. 

Imataki O, Kim SW, Kojima R, Hori A, Hamaki T, Sakiyama M, Murashige N, Satoh M, Kami M, Makimoto A, Takaue Y. Life-threatening hypothyroidism associated with administration of cyclosporine in a patient treated with reduced-intensity hematopoietic stem-cell transplantation for metastatic renal-cell carcinoma. Transplantation 2003 75 898-907. 

Differential diagnosis of graft-versus-host disease currently depends on organ biopsy to distinguish it from other common complications associated with transplantation. As a means of avoiding repeated biopsies, one group analyzed the urine of patients after hematopoietic stem cell transplantation... 

Kaiser T, Kamal H, Rank A, et al. Proteomics applied to the clinical follow-up of patients after allogeneic hematopoietic stem cell transplantation. Blood 2004 104(2) 340-349. 

Autologous hematopoietic stem cell transplantation (AHSCT) was evaluated in a group of MS patients with aggressive and advanced disease (Nash et al., 2003) with some promise but also wkh evidence that neurologic loss continued. One important hypothesis from that study was the discordant nature of inflammatory measures and functional deficits (Healey et al., 2004). 

Plasmapheresis is effective in patients with severe neuropsychiatric SLE refractory to conventional treatment. Intrathecal methotrexate and dexamethasone is also beneficial to those patients (Dong et al., 2001 Baca et al., 1999). Positive results of a phase I/II trial of autologous hematopoietic stem cell transplantation (AHSCT) at Northwestern University in Chicago, UL has led to a phase III ASCT trial. As with other similar trials involving autoimmune disease, the ASCT trial is designed to include standard of care IV pulse cyclophosphamide (Burt et al., 2003b). 

Nilsson C, Aschan J, Hentschke P, Ringden O, Ljnngman P, Hassan M. The effect of metronidazole on bnsnlfan pharmacokinetics in patients nndergoing hematopoietic stem cell transplantation. Bone Marrow Transplant 2003 31(6) 429-35. 

The difficulty in determining dose delivered with oral administration of high-dose busulfan in preparative regimens for hematopoietic stem cell transplantation results in lethal toxicity due to overdosing and increased potential for relapse with recurrent disease. Oral pharmacokinetic studies ineffectively determine proper AUC for reliable establishment for a proper therapeutic dose. Studies with IV formulations have demonstrated that all patients are evaluable. With the development of a limited sampling strategy to analyze proper AUC over intermittent time periods, improved patient risk profiles for busulfan have been implemented in clinical practice. 

Herrmann, R.P. Leather, M. Leather, H.L. Leen, K. Clinical care for patients receiving autologous hematopoietic stem cell transplantation in the home setting. Oncol. Nurs. Forum 1998, 25, 1427-1432. 

---